Business Wire

SoSafe hires former Smartly.io exec and SaaS leader Felix Fichtl as CFO to continue the firm’s recent growth

Share

SoSafe – a leading provider of cyber security awareness – has hired former Smartly.io exec and experienced SaaS operator Felix Fichtl as CFO.

Fichtl brings with him more than a decade’s experience in building and scaling finance organisations across the SaaS industry. From both his previous role as CFO at the global social media advertising automation giant, Smartly.io to his time spearheading finance operations for market leaders zoovu (formerly SMARTASSISTANT) and SAP Hybris (now SAP CX).

His appointment comes as SoSafe looks to build on its recent growth and bring its human-centric approach to cybersecurity to the assistance of even more companies on an international scale. SoSafe is currently the market leader in cybersecurity awareness in its home country of Germany, and is one of the leading providers across Europe.

In January 2022, the company closed a $73 million Series B financing round, led by Highland Europe, to help fuel expansion into new territories and establish the firm as the global market leader. Part of these plans involve further bolstering the strength, experience and expertise of the existing C-suite team, of which Fichtl will now play a pivotal role.

With its data-driven and human-centric platform, SoSafe takes a unique, behavioural science approach to cybersecurity. An approach pioneered by its founder and CEO, psychologist Hellemann. Founded on the idea that 85% of cyberattacks on companies and organisations can be traced back to a human factor, SoSafe embeds deep gamification elements into the workflows of employees to foster and scale effective corporate security cultures.

SaaS industry leader Felix Fichtl from Smartly.io strengthens SoSafe's leadership team

During his tenure at Smartly.io, Fichtl scaled the finance organization and played a key role in the sale of a majority stake of the company to Providence Equity in 2019. During his time at SAP Hybris, he managed the post-merger integration of the Hybris side before taking responsibility as Division CFO for SAP Hybris (now SAP CX).

"SoSafe has a crystal-clear value proposition that addresses a key concern for companies worldwide. The company is well on its way to becoming a global champion in the area of cyber security," says Fichtl. ”Smartly.io, while initially a European player, became a global market leader during my time there. We need more of these success stories and I feel SoSafe has the potential to see such similar success. I am impressed by the team and the investors behind SoSafe and look forward to working with them," he adds.

“SoSafe’s C-level is brimming with experienced industry leaders, broad-based and complementary competencies, clear lines of responsibility and transparent structures. With Felix, we have gained an outstanding executive who perfectly complements this team," says Hellemann. “His appointment not only demonstrates our growth and our commitment to our customers, but it showcases our ambitions and will help us cement SoSafe as a global leader in cybersecurity awareness,” says Niklas Hellemann, co-founder and CEO of SoSafe.

SoSafe is currently scaling internationally and has recently opened hubs in Amsterdam, London, and Paris to manage new markets.

_______________

About SoSafe

SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by psychologist and former BCG consultant Niklas Hellemann, Digitalization Expert and previous McKinsey consultant Lukas Schaefer, and seasoned software engineer Felix Schuerholz. Today, it serves more than 2000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team now consists of more than 350 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.

Website: www.sosafe-awareness.com/

LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
For further questions please contact
Mrs. Laura Hartmann via
press@sosafe-awareness.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye